No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SNDX Syndax Pharmaceuticals
- 20.760
- +0.100+0.48%
Close May 22 16:00 ET
1.76BMarket Cap-6407P/E (TTM)
21.110High20.500Low841.77KVolume20.670Open20.660Pre Close17.52MTurnover0.99%Turnover RatioLossP/E (Static)84.99MShares25.34052wk High3.59P/B1.76BFloat Cap11.21552wk Low--Dividend TTM84.65MShs Float29.860Historical High--Div YieldTTM2.95%Amplitude3.390Historical Low20.815Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Barclays Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $32
Barclays analyst Peter Lawson maintains $Syndax Pharmaceuticals(SNDX.US)$ with a buy rating, and maintains the target price at $32.According to TipRanks data, the analyst has a success rate of 44.1% a
Express News | JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Maintains $34 Price Target
Express News | Syndax Pharmaceuticals Inc : JP Morgan Adds Stock to Its U.S. Analyst Focus List
Syndax Pharmaceuticals Welcomes New Board Member, Passes Resolutions
Express News | Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.d., Ph.d. to the Board of Directors
Syndax Pharmaceuticals (SNDX) Gets a Buy From Stifel Nicolaus
Comments
$Syndax Pharmaceuticals(SNDX.US$ Syndax Pharmaceuticals Says FDA Grants Priority Review to New Drug Application for Acute Leukemia Treatment
MT Newswires· 1 min ago
Syndax Pharmaceuticals (SNDX) said late Tuesday the US Food and Drug Administration has granted priority review for the company's new drug application for revumenib to treat relapsed or refractory acute leukemia, a type of cancer.
The company said the filing was assigned a prescription drug user fee act target action date of S...
MT Newswires· 1 min ago
Syndax Pharmaceuticals (SNDX) said late Tuesday the US Food and Drug Administration has granted priority review for the company's new drug application for revumenib to treat relapsed or refractory acute leukemia, a type of cancer.
The company said the filing was assigned a prescription drug user fee act target action date of S...
Syndax Pharmaceuticals' excess liquidity indicates a cautious approach to debt, but its lack of significant operating revenue and EBIT loss over the last year are worrying. The company's balance sheet appears liquid, but the absence of regular free cash flow generation is concerning.
$Syndax Pharmaceuticals(SNDX.US$ Syndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program
3 MINUTES AGO, 7:00 AM EDT
VIA PR NEWSWIRE
3 MINUTES AGO, 7:00 AM EDT
VIA PR NEWSWIRE
$Syndax Pharmaceuticals(SNDX.US$ See a lot of potential here? with price action after trial PR, its like everyone read ( trial stopped early ) but didn’t read any further? it was stopped for efficacy, it showed improvement and are moving on to next phase!
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg